Lavipharm: First Half 2023 Financial Results

Strong EBITDA increase

Peania, 21 September 2023– Lavipharm (LAVI) reports a significant increase in consolidated sales and EBITDA during the First Half of 2023. The impressive results exceed sales forecasts, as disclosed in the prospectus of the recent share capital increase, for a second consecutive year.

Please refer to the attachment for the announcement.

Please see attached.